Primary cutaneous/subcutaneous Ewings sarcoma.

Area of Science:

• Oncology
• Pathology
• Surgical Oncology

Background:

• Cutaneous/subcutaneous Ewing sarcoma family of tumours (EFST) are rare, distinct entities arising from superficial tissues.
• These tumors are characterized by specific clinical presentations, often smaller than classical Ewing sarcoma and with a predilection for distal, truncal, and head/neck locations.

Purpose of the Study:

• To define the diagnostic and treatment strategies for cutaneous/subcutaneous Ewing sarcoma family of tumours.
• To outline prognostic factors and tailored therapeutic approaches based on tumor size and metastatic status.

Main Methods:

• Review of published literature and ESMO guidelines for soft-tissue tumours.
• Emphasis on core needle biopsy for diagnosis and molecular confirmation (EWSR1 rearrangement).
• Discussion of neoadjuvant/adjuvant chemotherapy, surgical management, and imaging for staging.

Main Results:

• Localized EFST (<200mL) can be treated with less intensive chemotherapy protocols (e.g., Saint Jude's regimen) to minimize toxicity.
• Larger tumors may require the classical VDC/IE protocol.
• Metastatic EFST has a poor prognosis, similar to classical Ewing sarcoma, necessitating aggressive management.

Conclusions:

• EFST requires management in specialized centers with a multidisciplinary approach.
• Treatment should balance curability with minimizing acute and late toxicities, particularly for localized disease.
• Surgical resection is preferred for local control, aiming to avoid radiotherapy when feasible.